Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine
- PMID:19022226
- DOI: 10.1016/j.bcp.2008.10.024
Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine
Abstract
Investigations using insect cell microsomes with cDNA-expressed human cytochrome P450 (CYP)s and human liver microsomes (HLM) are reported on the CYP isoenzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) to O-deethyl PCEEA and N-(1-phenylcyclohexyl)-2-methoxyethanamine (PCMEA) to O-demethyl PCMEA. Gas chromatography-mass spectrometry or liquid chromatography-mass spectrometry was used for the analysis of the incubation samples. PCEEA O-deethylation was catalyzed by CYP2B6, CYP2C9, CYP2C19, and CYP3A4, while PCMEA O-demethylation was catalyzed only by CYP2B6 and CYP2C19. Considering the relative activity factor approach, these enzymes accounted for 53%, 25%, 4%, and 18% of net clearance for PCEEA and 91% and 9% of net clearance for PCMEA, respectively. The chemical CYP2B6 inhibitor 4-(4-chlorobenzyl)pyridine (CBP) reduced the metabolite formation in pooled HLM by 63% at 1 microM PCEEA. At 10 microM PCEEA, CBP reduced metabolite formation by 61%, while inhibition of CYP3A4 by ketoconazole and inhibition of CYP2C9 by sulfaphenazole showed no inhibitory effect. At 1 microM PCMEA, CBP reduced metabolite formation in pooled HLM by 70% and at 10 microM PCMEA by 78%, respectively. In conclusion, the main metabolic step of both studied drugs was catalyzed by different CYPs.
Similar articles
- Identification of cytochrome P450 enzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-3-ethoxypropanamine and N-(1-phenylcyclohexyl)-3-methoxypropanamine.Sauer C, Peters FT, Schwaninger AE, Meyer MR, Maurer HH.Sauer C, et al.Chem Res Toxicol. 2008 Oct;21(10):1949-55. doi: 10.1021/tx8001302. Epub 2008 Sep 9.Chem Res Toxicol. 2008.PMID:18778087
- New designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and N-(1-phenylcyclohexyl)-2-methoxyethanamine (PCMEA): Studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques.Sauer C, Peters FT, Staack RF, Fritschi G, Maurer HH.Sauer C, et al.J Mass Spectrom. 2008 Mar;43(3):305-16. doi: 10.1002/jms.1312.J Mass Spectrom. 2008.PMID:17968862
- Use of fission yeast heterologously expressing human cytochrome P450 2B6 in biotechnological synthesis of the designer drug metabolite N-(1-phenylcyclohexyl)-2-hydroxyethanamine.Peters FT, Dragan CA, Schwaninger AE, Sauer C, Zapp J, Bureik M, Maurer HH.Peters FT, et al.Forensic Sci Int. 2009 Jan 30;184(1-3):69-73. doi: 10.1016/j.forsciint.2008.12.001. Epub 2009 Jan 9.Forensic Sci Int. 2009.PMID:19135815
- Metabolism of designer drugs of abuse: an updated review.Meyer MR, Maurer HH.Meyer MR, et al.Curr Drug Metab. 2010 Jun 1;11(5):468-82. doi: 10.2174/138920010791526042.Curr Drug Metab. 2010.PMID:20540700Review.
- Biotechnological synthesis of drug metabolites using human cytochrome P450 isozymes heterologously expressed in fission yeast.Peters FT, Bureik M, Maurer HH.Peters FT, et al.Bioanalysis. 2009 Jul;1(4):821-30. doi: 10.4155/bio.09.53.Bioanalysis. 2009.PMID:21083140Review.
Cited by
- Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.Wu C, Jiang XL, Shen HW, Yu AM.Wu C, et al.Biochem Pharmacol. 2009 Sep 15;78(6):617-24. doi: 10.1016/j.bcp.2009.05.011. Epub 2009 May 13.Biochem Pharmacol. 2009.PMID:19445902Free PMC article.
- New Psychoactive Substances 3-Methoxyphencyclidine (3-MeO-PCP) and 3-Methoxyrolicyclidine (3-MeO-PCPy): Metabolic Fate Elucidated with Rat Urine and Human Liver Preparations and their Detectability in Urine by GC-MS, "LC-(High Resolution)-MSn" and "LC-(High Resolution)-MS/MS".A Michely JA, Manier SK, Caspar AT, Brandt SD, Wallach J, Maurer HH.A Michely JA, et al.Curr Neuropharmacol. 2017;15(5):692-712. doi: 10.2174/1570159X14666161018151716.Curr Neuropharmacol. 2017.PMID:27758707Free PMC article.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources